Reminyl Cr Range 8mg. 16mg. 24mg Prolonged Release Capsules
PDF Leaflet Revision Date: 26 July 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Dosage (summary)
Starting dose: 8 mg/day for 4 weeks; Maintenance: 16 mg/day, may increase to 24 mg/day after assessment.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- CYP2D6 inhibitors
- CYP3A4 inhibitors
Contraindications
- Hypersensitivity to galantamine
- Severe renal impairment
- Severe hepatic impairment
- Urinary outflow obstruction
Common side effects
- Nausea
- Dizziness
- Fatigue
- Bradycardia
Counselling Points
- Monitor for signs of serious skin reactions.
- Take with food.
- Regularly reassess clinical benefit.
Serious warnings
- Serious skin reactions
- Weight loss monitoring
Important Disclaimer
The Reminyl Cr Range 8mg. 16mg. 24mg Prolonged Release Capsules professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
